overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
Published 1 year ago • 558 plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
1:42
adaura: the benefit of adjuvant osimertinib
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
8:06
adaura: osimertinib post-tumor resection in nsclc
-
4:24
reflections on the adaura study
-
1:46
osimertinib after surgery significantly improves survival in resected egfr-mutated nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
11:37
asco23 - lba3: os analysis from the adaura trial of adjuvant osimertinib in resected egfr‐mutate...
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
5:12
adaura trial: tagrisso & resectable egfr - leading developments & current questions in lung cancer
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
1:50
consolidation therapy for unresectable stage iii egfr-mutant nsclc
-
4:22
advanced-stage nsclc: overall survival data from flaura
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
3:52
is adjuvant chemotherapy in egfr mutated nsclc still required?
-
2:06
final overall survival (os) data from flaura trial